Posted in | News | Nanomedicine

BIND and Merck Partner to Develop Accurin Nanomedicines for Oncology

BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today announced a joint research and development agreement with Merck, known as MSD outside the United States and Canada, through a subsidiary, to discover and develop novel nanomedicines for oncology.

This collaboration will leverage BIND’s proprietary nanomedicine technology to create targeted Accurins based on novel, potent payloads from Merck’s preclinical oncology portfolio.

The first two Merck compounds include a kinesin spindle protein (KSP) inhibitor and a polo-like kinase 1 (PLK1) inhibitor. Both KSP and PLK1 are regulators of cellular mitosis and are considered essential to the proliferation of cancer cells. These pathways have proven difficult to target effectively using conventional agents due to therapeutic index limitations.

“This is an exciting and unique collaboration for BIND as it provides us with novel proprietary payloads to develop as Accurin product candidates for our internal pipeline,” said Scott Minick, Chief Executive Officer of BIND Therapeutics. “The structure of this agreement marks an advancement in our collaboration approach and demonstrates the strength of our leadership position in the field of nanomedicine.”

“We are pleased to collaborate with BIND Therapeutics to expand Merck’s active oncology discovery programs,” said Dr. Eric Rubin, vice president, clinical oncology, Merck Research Laboratories. “Merck is focused on exploring immuno-oncology and other promising pathways, and we look forward to combining compounds from our oncology portfolio with BIND’s nanomedicine technology platform.”

Under the terms of the agreement, BIND will apply its Medicinal Nanoengineering® platform to develop targeted Accurins based initially on Merck-supplied investigational KSP and PLK1 inhibitors. The agreement also includes the option to incorporate additional Merck compounds in the future. BIND will fund and conduct research and development activities to advance Accurin product candidates based on these agents through first-in-human clinical studies, after which Merck and BIND will alternate in choosing whether or not to further develop and commercialize the Accurin products. If BIND opts in, in most scenarios there will be no payments made to Merck beyond a royalty on future product sales. If Merck opts in, it will pay BIND a fee based on a multiple of BIND’s research and development expenses, plus a royalty on future product sales. Further terms of the agreement were not disclosed.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.